Tissue microarrays for predictive molecular pathology
暂无分享,去创建一个
[1] T Hardmeier,et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. , 2001, Cancer research.
[2] H. Moch,et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.
[3] H. Moch,et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.
[4] H Buerger,et al. Tissue microarrays: a new approach for quality control in immunohistochemistry , 2002, Journal of clinical pathology.
[5] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Moch,et al. Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies , 2001, The Journal of pathology.
[7] D. Larsimont,et al. Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. , 2002, Journal of clinical pathology.
[8] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[9] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.